<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03270384</url>
  </required_header>
  <id_info>
    <org_study_id>PR1032</org_study_id>
    <nct_id>NCT03270384</nct_id>
  </id_info>
  <brief_title>Re-establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease</brief_title>
  <acronym>ROBUST-II</acronym>
  <official_title>Re-establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urotronic Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Urotronic Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study described below is designed to assess the safety and device performance for the
      drug coated balloon (DCB) for the treatment of urethral stricture.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety- Rate of Device Related Serious Complications</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety- Change in IIEF (International Index of Erectile Function)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy- Stricture Recurrence Rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Urethral Stricture</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 15 subjects will be enrolled and treated with the Urotronic drug coated balloon (DCB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Urotronic Drug Coated Balloon (DCB)</intervention_name>
    <description>The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male subjects â‰¥ 18 years' old

          2. Visual confirmation of stricture via cystoscopy or urethrogram

          3. Single lesion anterior urethral stricture less than or equal to 3 cm

          4. Two (2) or more prior diagnosis and treatment of stricture treatments (including
             self-catheterization) including DVIU (direct visual internal urethrotomy), but no
             prior urethroplasty

          5. Significant symptoms of stricture such as frequency of urination, dysuria, urgency,
             hematuria, slow flow, feeling of incomplete emptying, recurrent UTI's (urinary tract
             infections).

          6. IPSS (International Prostate Symptom Score) score of 13 or higher

          7. Lumen diameter &lt;12F by urethrogram

          8. Able to complete validated questionnaire independently

          9. Qmax &lt;12 ml/sec

         10. Guidewire must be able to cross the lesion

        Exclusion Criteria:

          1. Strictures greater than 3.0 cm long.

          2. Subjects that have more than 1 stricture.

          3. Sensitivity to paclitaxel or on medication that may have negative interaction with
             paclitaxel

          4. Subjects who have a suprapubic catheter

          5. Previous urethroplasty within the anterior urethra

          6. Stricture due to bacterial urethritis or untreated gonorrhea

          7. Stricture dilated or incised within the last 3 months

          8. History of over active bladder or stress incontinence

          9. Previous radical prostatectomy

         10. Previous pelvic radiation

         11. Diagnosed kidney, bladder, urethral or ureteral stones or active stone passage in the
             past 6 months.

         12. Presence of a penile implant, artificial urinary sphincter, or stent(s) in the urethra
             or prostate

         13. Known neurogenic bladder, sphincter abnormalities, or poor detrusor muscle function
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Elliott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Moffett</last_name>
    <phone>952-303-2821</phone>
    <email>moffettl@urotronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bradley Erickson, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Tammy Lowe</last_name>
      <email>tamara-lowe@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bradley Erickson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology</name>
      <address>
        <city>Hanover</city>
        <state>Maryland</state>
        <zip>21076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Paxton</last_name>
      <email>wpaxton@cua.md</email>
    </contact>
    <investigator>
      <last_name>Kaiser Robertson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sean Elliott, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Bethany Marlette</last_name>
      <email>marle025@umn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sean Elliott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Urology</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ehlert</last_name>
    </contact>
    <contact_backup>
      <last_name>Diane Kachel</last_name>
      <email>Dkachel@mnurology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Ehlert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Virasoro, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Adrienne Helvig</last_name>
      <email>AHelvig@urologyofva.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ramon Virasoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica DeLong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2017</study_first_submitted>
  <study_first_submitted_qc>August 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2017</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>early feasibility</keyword>
  <keyword>non-randomized</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Urethral Stricture</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

